Expanding the gamut of circulating tumor DNA applications

Historically, advanced non-small cell lung cancer (NSCLC) has been a devastating cancer diagnosis with an aggressive course and poor prognosis despite extensive and toxic therapy, however with the advent of personalized therapy targeting molecular aberrancies, the field of lung cancer has made significant advances in outcomes with concomitant improvements in toxicity profiles (1,2).